Financial Performance - The company's operating revenue for Q3 2025 was ¥2,123,816,858.34, representing a 6.10% increase year-over-year[4] - Net profit attributable to shareholders decreased by 58.74% to ¥32,464,179.69 for the same period[4] - The basic earnings per share fell by 54.55% to ¥0.05, while diluted earnings per share also decreased by 58.33% to ¥0.05[4] - The weighted average return on net assets declined by 1.00% to 0.63%[4] - Total operating revenue for the third quarter of 2025 reached CNY 6,762,620,901.32, a slight increase from CNY 6,734,166,240.75 in the same period last year, representing a growth of approximately 0.42%[16] - Net profit for the period was CNY 266,908,611.57, down from CNY 355,449,271.22, reflecting a decrease of approximately 25.0%[17] - Basic earnings per share decreased to CNY 0.37 from CNY 0.50, indicating a decline of 26.0%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,093,740,128.02, a 0.82% increase from the end of the previous year[4] - Total assets amounted to CNY 9,093,740,128.02, compared to CNY 9,019,601,567.53 in the previous year, showing a growth of about 0.82%[15] - Total liabilities decreased to CNY 3,703,345,422.11 from CNY 3,802,101,150.19, a reduction of approximately 2.6%[15] - Long-term borrowings decreased significantly to CNY 498,319,527.08 from CNY 771,540,739.20, a decline of about 35.3%[15] Cash Flow - The net cash flow from operating activities increased by 26.65% to ¥321,998,862.97 year-to-date[4] - Operating cash flow for the current period is ¥321,998,862.97, an increase of 26.7% compared to ¥254,240,659.40 in the previous period[19] - Total cash inflow from operating activities is ¥5,857,712,171.91, down 2.5% from ¥6,005,619,921.41 in the previous period[19] - Cash outflow from operating activities is ¥5,535,713,308.94, a decrease of 3.7% compared to ¥5,751,379,262.01 in the previous period[19] - Net cash flow from investing activities is -¥95,943,641.64, an improvement from -¥140,775,569.51 in the previous period[19] - Cash inflow from financing activities totals ¥810,637,524.50, down 15.5% from ¥959,093,430.93 in the previous period[19] - Net cash flow from financing activities is -¥244,116,975.19, compared to a positive cash flow of ¥135,151,565.02 in the previous period[19] - The cash and cash equivalents at the end of the period amount to ¥1,124,937,483.16, an increase from ¥1,042,985,433.99 in the previous period[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,695[9] - The top two shareholders held a combined 57.75% of the company's shares, with Hualu Holdings Group Co., Ltd. owning 29.70%[9] - The company issued 37,091,988 shares of ordinary stock to Hualu Investment Development Co., Ltd., which were released from restrictions on April 14, 2025[11] - The total number of shareholders for preferred shares is not applicable, indicating no preferred shares were issued[11] - The company has not identified any related party relationships among the top shareholders, except for Hualu Investment Development Co., Ltd., which is a wholly-owned subsidiary of Hualu Holdings Group Co., Ltd.[11] Operational Adjustments - The company adjusted product prices to enhance market share in response to intense market competition, impacting net profit and earnings[7] - Research and development expenses were CNY 300,109,321.29, slightly down from CNY 326,669,940.69, indicating a decrease of approximately 8.1%[16] - The company reported an investment loss of CNY 6,102,717.35, compared to a profit of CNY 8,399,571.55 in the previous year[16] Other Financial Metrics - Non-operating income for the reporting period amounted to ¥4,267,303.02, with government subsidies contributing ¥9,600,936.95[5] - Total current assets as of September 30, 2025, amounted to CNY 3,898,783,848.79, an increase from CNY 3,726,840,162.91 at the beginning of the period[13] - Accounts receivable increased to CNY 1,021,148,062.81 from CNY 868,204,001.79, reflecting a growth of approximately 17.6%[13] - Inventory decreased slightly to CNY 1,252,463,607.93 from CNY 1,272,856,947.10, indicating a reduction of about 1.6%[13] - Cash and cash equivalents at the end of the period were CNY 1,234,429,753.94, down from CNY 1,245,022,873.47[13] - Prepayments increased significantly to CNY 66,471,212.13 from CNY 33,378,429.50, marking a growth of approximately 99.5%[13] - The company has not disclosed any significant changes in accounting policies during the reporting period[11] - The company is set to allow the exercise of stock options for 7,368,900 shares on January 14, 2025, as part of its stock option incentive plan[11] - The company received tax refunds of ¥57,238,889.51, a decrease of 58.3% from ¥137,300,816.13 in the previous period[19] - Cash paid for purchasing goods and services is ¥4,252,434,435.68, an increase of 1.0% compared to ¥4,208,317,081.25 in the previous period[19] - Cash paid to employees is ¥763,390,417.43, a decrease of 3.9% from ¥793,995,883.11 in the previous period[19]

格隆汇10月24日｜新华制药(0719.HK)在港交所发布公告称，2025年前三季度营收约67.63亿元，同比增 0.42%；归属于上市股东的净利润约2.56亿元，同比降25.53%。 ...

格隆汇10月24日丨山东新华制药股份(00719.HK)发布公告，2025年1-9月，实现营业收入67.63亿元(人民 币，下同)，同比增长0.42%；归属于上市公司股东的净利润2.56亿元，同比下降25.53%；归属于上市公 司股东的扣除非经常性损益的净利润2.39亿元，同比下降25.62%；基本每股收益0.37元。 ...

智通财经APP讯，山东新华制药股份(00719)发布截至2025年9月30日止九个月业绩，营业收入67.63亿元 (人民币，下同)，同比增长0.42%;归属于上市公司股东的净利润2.56亿元，同比下降25.53%;基本每股收 益0.37元。 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. reported a slight increase in revenue but a significant decline in net profit for the first nine months of 2025 compared to the previous year [1] Financial Performance - The company achieved a revenue of 6.763 billion RMB, representing a year-on-year growth of 0.42% [1] - The net profit attributable to shareholders decreased to 256 million RMB, down 25.53% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 239 million RMB, reflecting a decline of 25.62% year-on-year [1] - Basic earnings per share stood at 0.37 RMB [1]

香港交易及結算所有限公司及香港联合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 山 東 新 華 製 藥 股 份 有 限 公 司 （ 「 本 公 司 」 ） 將 於 2025 年 10 月 25 日 在 巨 潮 資 訊 網 （http://www.cninfo.com.cn）刊登的本公司《2025 年第三季度報告》,茲載列有關文檔之中文版， 以供參閱。 承董事會命 山東新華製藥股份有限公司 賀同慶 董事長 中國 淄博 2025年10月24日 於本公告日期，本公司董事會之成員如下： | 執行董事： | | 獨立非執行董事： | | --- | --- | --- | | 賀同慶先生（董事長） | | 潘廣成先生 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：00719） 重續持續關連交易之 商標許可協議 重續持續關連交易 茲提述山東新華製藥股份有限公司(「本公司」，連同其不時的附屬公司統稱為 「本集團」)日期分別為2009年10月28日、2012年3月23日、2014年10月27日、 2017年10月30日、2020年10月22日、2023年12月22日及2024年12月31日有關「新 華」商標（「商標」）許可的公告（統稱「該等公告」），該等公告構成本公司的持 續關連交易。除非文義另有所指，本公告所用詞彙與上述公告所界定者具相同涵 義。除另有界定外，本公告所界定詞彙具有該等公佈所界定的涵義。 鑒於本公司與華魯控股集團有限 ...

香港交易及結算所有限公司及香港联合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 山 東 新 華 製 藥 股 份 有 限 公 司 （ 「 本 公 司 」 ） 將 於 2025 年 10 月 25 日 在 巨 潮 資 訊 網 （http://www.cninfo.com.cn）刊登的本公司《第十一屆董事會第九次會議決議公告》及《第十一屆 監事會第九次會議決議公告》,茲載列有關文檔之中文版，以供參閱。 承董事會命 山東新華製藥股份有限公司 賀同慶 董事長 中國 淄博 2025年10月24日 证券代码：000756 证券简称：新华制药 公告编号：2025-60 於本公告日期，本公司董事會之成員如下： | 執行董事： | 獨立 ...

Financial Performance - For the nine months ended September 30, 2025, the company's operating revenue was RMB 6,762,620,901.32, representing a year-on-year increase of 0.42% compared to RMB 6,734,166,240.75 in the same period of 2024[6] - The net profit attributable to shareholders of the listed company for the same period was RMB 256,220,710.12, a decrease of 25.53% from RMB 344,079,950.67 in 2024[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 239,056,816.15, down 25.62% from RMB 321,411,536.21 in the previous year[6] - The basic and diluted earnings per share were both RMB 0.37, down 26.00% from RMB 0.50 in the previous year[7] - The comprehensive income attributable to shareholders of the parent company was RMB 251,366,971.67, down from RMB 419,303,408.85 in the same period last year[9] Cash Flow and Assets - The net cash flow from operating activities increased by 26.65% to RMB 321,998,862.97, compared to RMB 254,240,659.40 in the same period last year[7] - The total assets as of September 30, 2025, were RMB 9,093,740,128.02, reflecting a 0.82% increase from RMB 9,019,601,567.53 at the end of 2024[7] - The net assets attributable to shareholders of the listed company increased by 3.15% to RMB 5,149,027,624.51 from RMB 4,991,588,524.78 at the end of 2024[7] Operating Costs and Expenses - The total operating costs for the nine months ended September 30, 2025, were RMB 6,434,132,318.50, compared to RMB 6,337,089,365.67 in the same period of 2024[8] - The company's research and development expenses for the period were RMB 300,109,321.29, a decrease from RMB 326,669,940.69 in the previous year[8]

山東新華製藥股份有限公司 一間 于中 華人 民共 和國成 立的 中外 合資股 份有 限公 司 公 司 章 程 第八条 公司章程對公司及其股東、董事、總經理和其他高級管理人員均 有約束力；前述人員均可以依據公司章程提出與公司事宜有關的 權利主張。 股東可以依據公司章程起訴公司；公司可以依據公司章程起訴股 東、董事和高級管理人員；股東可以依據公司章程起訴股東；股 東可以依據公司章程起訴公司的董事、高級管理人員。 在公司控股股東單位擔任除董事以外其他行政職務的人員，不得 2 的文件。 第一条 本公司系依照《中華人民共和國公司法》（簡稱《公司法》）和 其他有關法律、行政法規成立的股份有限公司。 本公司 1993 年 9 月經山東省經濟體制改革委員會以魯體改生字 （1993）第 66 號文批准確認以定向募集方式設立，1996 年 8 月 經國家經濟體制改革委員會以體改生字（1996）116 號文確認為 到香港發行股票並上市的股份有限公司。公司於 1998 年 11 月 20 日在淄博市工商行政管理局重新註冊登記，取得公司營業執照。 公司統一社會信用代碼：91370300164103727C 公司的發起人為：山東新華製藥 ...